Reports summarize life sciences research from University of California, Department of Urology

Researchers detail in 'A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy,' new data in life sciences. According to a study from the United States, "To determine whether a multicolour fluorescence in situ hybridization test (UroVysion, Abbott Molecular Inc., Des Plaines, IL, USA) in patients with high-risk superficial bladder tumours maintains its predictive ability in a multivariate model for recurrence and progression, incorporating clinical and pathological predictors of outcome. The charts of patients with superficial bladder cancer treated with induction or maintenance...

Want to see the full article?

• Purchase this article for only $3.00